People with sickle cell anemia (SCA) may undergo fertility preservation (FP) due to risks of diminished ovarian reserve (DOR) and curative therapy regimens. Ovarian tissue, oocytes or embryos may be cryopreserved; pubescent individuals with ovaries are offered controlled ovarian hyperstimulation (COH) with oocyte cryopreservation (OC). Little data addresses FP outcomes in SCA. FP benefits are balanced against procedural risks, potential low oocyte yield with DOR, and access barriers. The purpose of this study is to describe clinical factors associated with oocyte recovery and COH complications in SCA, as Marti Goldenberg (Department of Pediatric Hematology, Johns Hopkins Hospital, Baltimore), whom we met at the ASH 2024 conference in San Diego, explains.